Delayed Finalization of Sodium Targets in the United States May Cost Over 250 000 Lives by 2031.

These findings highlight the enormous health costs due to the FDA's delay in finalizing the sodium-reduction targets, and the great potential health benefits of industry compliance with the FDA's finalization of its short- and long-term targets in the coming 10 years.